Canni Med will be more valuable as a company that offers both medical and recreational products.
Canni Med will be well positioned to offer a diversity of products, thereby enabling market segmentation, reducing customer churn, and making the company more competitive domestically and internationally.
The premium currently implied by the proposed exchange ratio is inflated and is based on the recent substantial and inexplicable run up in Aurora’s share price – 110 per cent (from .05 to .41) over the two weeks leading up to Aurora’s announcement of its intention to launch the Hostile Bid.
This significant run up in share price is not based on substantive decisions or value created by Aurora’s management.
The combined company will offer a class-leading portfolio of innovative, high quality products that will be uniquely positioned to address key product trends and emerging drivers of growth in both the medical and adult use recreational cannabis markets.
A management team Canni Med Shareholders can trust.